Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Interferon-alpha treatment for severe atopic dermatitis

H Kimata1, Y Akiyama, M Kubota

  • 1Department of Pediatrics, Kyoto University Hospital, Japan.

Allergy
|October 1, 1995
PubMed
Summary

Interferon-alpha (IFN-alpha) therapy improved severe atopic dermatitis (AD) in patients with certain cancers or hepatitis. The treatment also reduced immunoglobulin levels, indicating a potential dual benefit for these conditions.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Potential role for S100A4 in the disruption of the blood-brain barrier in collagen-induced arthritic mice, an animal model of rheumatoid arthritis.

Neuroscience·2011
Same author

Assessment of laughter by diaphragm electromyogram.

European journal of clinical investigation·2008
Same author

Specific allergen enhances IgE production via galectin-3 in surface IgE+ B cells.

European journal of clinical investigation·2007
Same author

Elevation of salivary melatonin levels by viewing a humorous film in patients with atopic eczema.

Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme·2007
Same author

Anaphylaxis by stevioside in infants with atopic eczema.

Allergy·2007
Same author

Clinical experiment of mutant herpes simplex virus HF10 therapy for cancer.

Current cancer drug targets·2007

Area of Science:

  • Immunology
  • Dermatology
  • Hepatology
  • Oncology

Background:

  • Severe atopic dermatitis (AD) is a chronic inflammatory skin condition.
  • Co-existing conditions like chronic myeloid leukemia, hepatitis B, or hepatitis C can complicate patient management.
  • The role of interferon-alpha (IFN-alpha) in modulating immune responses in AD requires further investigation.

Purpose of the Study:

  • To evaluate the effect of interferon-alpha (IFN-alpha) on severe atopic dermatitis (AD).
  • To assess changes in serum immunoglobulin E (IgE) and immunoglobulin G4 (IgG4) levels during IFN-alpha treatment.
  • To investigate the impact of IFN-alpha on in vitro spontaneous IgE and IgG4 production.

Main Methods:

  • A cohort of patients with severe AD and co-existing chronic myeloid leukemia, chronic hepatitis B, or chronic hepatitis C were treated with IFN-alpha.

Related Experiment Videos

  • Clinical assessment of AD severity was performed.
  • Serum levels of IgE and IgG4 were measured.
  • In vitro spontaneous IgE and IgG4 production by peripheral blood mononuclear cells was assessed.

    • Main Results:

    • IFN-alpha treatment led to significant improvement in severe atopic dermatitis (AD).
    • Patients exhibited notable reductions in serum IgE and IgG4 levels.
    • A significant decrease in in vitro spontaneous IgE and IgG4 production by mononuclear cells was observed.

    Conclusions:

    • Interferon-alpha (IFN-alpha) therapy demonstrates efficacy in improving severe atopic dermatitis (AD) in patients with specific comorbidities.
    • IFN-alpha treatment is associated with a reduction in key immunoglobulin levels (IgE, IgG4), suggesting a broader immunomodulatory effect.
    • These findings highlight a potential therapeutic benefit of IFN-alpha beyond its primary indication, impacting both AD and immune markers.